BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikins Vaccines for Infectious Diseases and Cancer


6/20/2012 10:30:17 AM

LONDON, June 19, 2012 /PRNewswire/ -- The Foundation for Research on the Nervous System, Replikins Ltd., and Bioradar UK Ltd. today announced that over 100 new synthetic Replikins vaccines for infectious diseases and cancer are now available as a result of the discovery by scientists Drs. Samuel and Elenore Bogoch of the evolution of the genomic Replikins over time -- from ocean archaea to human cancer. A book on this subject will be released in September 2012.

Peak Gene Replikin Count: http://www.ereleases.com/pic/2012-Peak-Gene-Replikin-Count.jpg

Drs. Bogoch have determined that the highest peak gene Replikin Counts are six-fold greater in brain cancer than the Counts in ocean archaea and viruses. The ability to specify certain increasing genomic sequences related to lethality has permitted new synthetic vaccines for organisms such as Taura Syndrome Virus, infectious salmon anemia virus, universal influenza virus strains, highly lethal drug-resistant tuberculosis, and malaria, and cancers of histological type with the highest five-year mortality rates for which vaccines have not previously been available.

Because these Replikins genomic sequences have been shown to provide 1-2 years advance notice of outbreaks, effective synthetic vaccines have been manufactured by the Companies in seven days, providing time for adequate testing, and can be delivered in freeze-dried form in literally limitless quantities.

References

Accounts of some of the work on individual products have been published 1) in eight papers in Nature Precedings 2011-2012 (http://bit.ly/MdaG8m); 2) on the companies' website (http://www.Replikins.com), which contains over 40 news announcements from 2006-present; and 3) in patent publications from 2002-present.

Contact: Dr. S. Bogoch, 646-320-5910

This press release was issued through eReleasesĀ® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Replikins Ltd.



Read at BioSpace.com

Replikins
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES